Search research articles
Contact Us
Filters
Showing results (51-60 of 105) with videos related to
Page
of 11
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
March 27, 2018
Clinical Features and Management of Acquired Resistance to PD-1 Axis Inhibitors in 26 Patients With Advanced Non-Small Cell Lung Cancer
Scott N Gettinger, Anna Wurtz, Sarah B Goldberg, et al.
The Lancet. Oncology
|
February 10, 2016
Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study
Scott Antonia, Sarah B Goldberg, Ani Balmanoukian, et al.
Cancer
|
October 29, 2020
Comparative efficacy of chemoimmunotherapy versus immunotherapy for advanced non-small cell lung cancer: A network meta-analysis of randomized trials
Ranjan Pathak, Gilberto De Lima Lopes, Han Yu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 2, 2020
PD-1/PD-L1 Blockers in NSCLC Brain Metastases: Challenging Paradigms and Clinical Practice
Iñaki Eguren-Santamaria, Miguel F Sanmamed, Sarah B Goldberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 17, 2022
Circulating Tumor DNA Kinetics Predict Progression-Free and Overall Survival in EGFR TKI-Treated Patients with EGFR-Mutant NSCLC (SWOG S1403)
Philip C Mack, Jieling Miao, Mary W Redman, et al.
Nature Communications
|
November 10, 2022
Biochemical and structural basis for differential inhibitor sensitivity of EGFR with distinct exon 19 mutations
Iris K van Alderwerelt van Rosenburgh, David M Lu, Michael J Grant, et al.
JAMA Oncology
|
April 17, 2025
Adoption of Broad Genomic Profiling in Patients With Cancer
Xiao Wang, John Rothen, Sida Huang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
October 8, 2023
Co-Occurring Alterations in Multiple Tumor Suppressor Genes Are Associated With Worse Outcomes in Patients With EGFR-Mutant Lung Cancer
Paul Stockhammer, Michael Grant, Anna Wurtz, et al.
British Journal of Clinical Pharmacology
|
December 1, 2022
Population pharmacokinetic modelling of tremelimumab in patients with advanced solid tumours and the impact of disease status on time-varying clearance
Michael Hwang, Yen Lin Chia, Yanan Zheng, et al.
Expert Opinion on Investigational Drugs
|
June 3, 2022
A phase 1b/2 study of PF-06747775 as monotherapy or in combination with Palbociclib in patients with epidermal growth factor receptor mutant advanced non-small cell lung cancer
Byoung Chul Cho, Sarah B Goldberg, Dong-Wan Kim, et al.
Page
of 11
Search research articles
Search
Showing results (51-60 of 105) with videos related to
Sort By:
Page
of 11
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
March 27, 2018
Clinical Features and Management of Acquired Resistance to PD-1 Axis Inhibitors in 26 Patients With Advanced Non-Small Cell Lung Cancer
Scott N Gettinger, Anna Wurtz, Sarah B Goldberg, et al.
The Lancet. Oncology
|
February 10, 2016
Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study
Scott Antonia, Sarah B Goldberg, Ani Balmanoukian, et al.
Cancer
|
October 29, 2020
Comparative efficacy of chemoimmunotherapy versus immunotherapy for advanced non-small cell lung cancer: A network meta-analysis of randomized trials
Ranjan Pathak, Gilberto De Lima Lopes, Han Yu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 2, 2020
PD-1/PD-L1 Blockers in NSCLC Brain Metastases: Challenging Paradigms and Clinical Practice
Iñaki Eguren-Santamaria, Miguel F Sanmamed, Sarah B Goldberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 17, 2022
Circulating Tumor DNA Kinetics Predict Progression-Free and Overall Survival in EGFR TKI-Treated Patients with EGFR-Mutant NSCLC (SWOG S1403)
Philip C Mack, Jieling Miao, Mary W Redman, et al.
Nature Communications
|
November 10, 2022
Biochemical and structural basis for differential inhibitor sensitivity of EGFR with distinct exon 19 mutations
Iris K van Alderwerelt van Rosenburgh, David M Lu, Michael J Grant, et al.
JAMA Oncology
|
April 17, 2025
Adoption of Broad Genomic Profiling in Patients With Cancer
Xiao Wang, John Rothen, Sida Huang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
October 8, 2023
Co-Occurring Alterations in Multiple Tumor Suppressor Genes Are Associated With Worse Outcomes in Patients With EGFR-Mutant Lung Cancer
Paul Stockhammer, Michael Grant, Anna Wurtz, et al.
British Journal of Clinical Pharmacology
|
December 1, 2022
Population pharmacokinetic modelling of tremelimumab in patients with advanced solid tumours and the impact of disease status on time-varying clearance
Michael Hwang, Yen Lin Chia, Yanan Zheng, et al.
Expert Opinion on Investigational Drugs
|
June 3, 2022
A phase 1b/2 study of PF-06747775 as monotherapy or in combination with Palbociclib in patients with epidermal growth factor receptor mutant advanced non-small cell lung cancer
Byoung Chul Cho, Sarah B Goldberg, Dong-Wan Kim, et al.
Page
of 11